Xpovio (selinexor) — Highmark

Initial criteria

• age ≥ 18 years
• diagnosis of MM (ICD-10: C90)
• use in combination with bortezomib and dexamethasone
• has received at least one prior therapy for MM

Reauthorization criteria

• prescriber attests member is tolerating therapy AND has experienced therapeutic response defined as disease improvement OR delayed disease progression

Approval duration

12 months